227609-88-3

Usage

Uses

Used in Pharmaceutical Industry:
4-FLUORO-3-IODOBENZALDEHYDE is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-FLUORO-3-IODOBENZALDEHYDE is utilized as a building block for the creation of agrochemicals, playing a role in the development of pesticides and other agricultural chemicals to enhance crop protection and yield.
Used in Materials Science:
4-FLUORO-3-IODOBENZALDEHYDE is employed as a versatile reagent in materials science for its potential to form various functional groups and heterocycles, which are essential in the advancement of new materials with specific properties for different applications.
Used in Organic Synthesis:
As a crucial component in organic synthesis, 4-FLUORO-3-IODOBENZALDEHYDE is used to facilitate a range of chemical reactions, enabling the production of complex organic molecules that can be applied across multiple industries.

InChI:InChI=1/C7H4FIO/c8-6-2-1-5(4-10)3-7(6)9/h1-4H

Upstream product

• 227609-87-2 (4-fluoro-3-iodophenyl)methanol 
• 459-57-4 4-fluorobenzaldehyde 
• 452-82-4 1-fluoro-2-iodo-4-methylbenzene 
• 227609-86-1 (3-amino-4-fluorophenyl)methanol 
• 2365-85-7 3-amino-4-fluorobenzoic acid 
• 260050-97-3 4-(bromomethyl)-1-fluoro-2-iodobenzene 

Downstream Products

• 497098-26-7 methyl 2-ethyl-4-(4-fluoro-3-iodophenyl)-5-oxo-4,5,6,8-tetrahydro-1H-pyrano[3,4-b]pyridin-3-carboxylate 
• 550363-85-4 2-fluoro-5-formyl-benzoic acid 
• 1599529-24-4 2,2,2-trifluoro-1-(2-fluoro-5-((4-fluorophenyl)(hydroxy)methyl)phenyl)ethanone 

Relevant academic research and scientific papers

Practical Synthesis of (3a R, 9b R)-8-Fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1 H-benzo[e]indole: An Advanced Intermediate to Access the RORγt Inverse Agonist BMT-362265

A practical and scalable route to (3aR, 9bR)-8-fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole 10, an advanced intermediate en route to the synthesis of the RORγt inverse agonist, BMT-362265, is described starting from fluorobenzene. The synthesis involved the screening of multiple synthetic routes for their feasibility and scalability. We also demonstrate the utility of an annulating reagent, (R)-N-(2-chloroethyl)-2-methylpropane-2-sulfinamide, for the diastereoselective synthesis of tricyclic pyrrolidine intermediates 24 and 36 on a multigram scale.

METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

Oxidative iodination of deactivated arenes in concentrated sulfuric acid with I2/NaIO4 and KI/NaIO4 iodinating systems

Deactivated arenes were mono- or diiodinated with strong electrophilic I+ reagents, which were prepared from NaIO4 and either I2 or KI in concentrated H2SO4 (minimum 95% by weight). In general a small excess of the dark brown iodinating solution was used (1.1/1.5 equivalents, for nitrobenzene two equivalents was required). The iodinations were conducted at 25-30 °C with a reaction time of 1-2 hours using either a 'direct' or an 'inverse' method of aromatic iodination to give mono- or diiodinated pure products in 31-91% optimized yields. Georg Thieme Verlag Stuttgart.

An improved synthesis of Pyran-3,5-dione: Application to the synthesis of ABT-598, a potassium channel opener, via Hantzsch reaction

Ketoester 1 is cyclized to give pyran-3,5-dione 2 in 78% yield using a parallel addition of ketoester 1 and base NaOtBu in refluxing THF. Compared to the previously reported procedures, these optimized conditions have significantly increased the yield of this transformation and the quality of pyran 2 and prove to be suitable for large-scale preparation. An application of 2 to the synthesis of ABT-598, a potassium channel opener, is demonstrated.

Protein-tyrosine phosphatase inhibitors and uses thereof

The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.

Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinoline-8(4H)-one 1,1-dioxide K ATP channel openers: Discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent KATP opener that selectively inhibits spontaneous bladder contractions

Structure-activity relationships were investigated on a novel series of sulfonyldihydropyridine-containing KATP openers. Ring sizes, absolute stereochemistry, and aromatic substitution were evaluated for K ATP activity in guinea pig bladder cells using a fluorescence-based membrane potential assay and in a pig bladder strip assay. The inhibition of spontaneous bladder contractions in vitro was also examined for a select group of compounds. All compounds studied showed greater potency to inhibit spontaneous bladder contractions relative to their potencies to inhibit contractions elicited by electrical stimulation. In an anesthetized pig model of myogenic bladder overactivity, compound 14 and (-)-cromakalim 1 were found to inhibit spontaneous bladder contractions in vivo at plasma concentrations lower than those that affected hemodynamic parameters. Compound 14 showed approximately 5-fold greater selectivity than 1 in vivo and supports the concept that bladder-selective KATP channel openers may have utility in the treatment of overactive bladder.

Fragment screening and assembly: A highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor

Using an NMR-based fragment screening and X-ray crystal structure-based assembly, starting with millimolar ligands for both the catalytic site and the second phosphotyrosine binding site, we have identified a small-molecule inhibitor of protein tyrosine phosphatase 1B with low micromolar inhibition constant, high selectivity (30-fold) over the highly homologous T-cell protein tyrosine phosphatase, and good cellular activity in COS-7 cells.

Iodination of 4-fluoro-benzaldehyde

The present invention relates to an improved process for iodinating a substituted benzaldehyde.

Novel radioligands and their use for identifying potassium channel modulators

The present invention relates to novel radioligands and test methods using those radioligands in screening compounds.